Background
Methods
Statistical analyses
Results
Controls | Primary/Secondary syphilis | Latent Syphilis | |||
---|---|---|---|---|---|
(n = 30) | HIV+ (n = 44)#
| HIV-(n = 10)#
| HIV+ vs. HIV-, P$
| HIV+(n = 35)#
| |
Men | 30 (100%) | 44 (100%) | 9 (90%)* | 0.0359 | 35 (100%) |
Age (years) | 37 (32–45) | 39.5 (30.5–50.0) | 34 (30–43) | 0.4689 | 40 (35–46) |
MSM | 24 (80%) | 44 (100%) | 9 (90%) | 0.0359 | 34 (94.7.1%) |
CD4 T cell count (cells per μL) | 577 (392–684) | 649 (452–838) | 800 (800–800) | 0.4537 | 590 (433–691) |
HIV Viral Load (copies per mL) | 34 (10–814) | 10 (10–53)* | NA | NA | 10 (10–25)** |
On Antiretroviral Therapy | 24 (80%) | 39 (88.6%) | NA | NA | 31 (88.6%) |
RPR titre | 0 (0–0) | 1/64 (1/32–1/128) | 1/64 (1/16–1/128) | 0.5556 | 1/64 (1/16–1/128) |
Treatment | 1.0 | ||||
Benzathine-penicillin G | NA | 44 (100%) | 10 (100%) | 33 (94.3%) | |
Doxycycline | NA | 0 | 0 | 2 (5.7%) | |
Previous treated syphilis | NA | 27 (61.3%) | 3 (30%) | 0.0743 | 24 (68.6%) |
Other STIs presenta
| 0 (30) | 1 (2.3%) | 0 (0%) | 0.63 | 2 (5.7%) |
No. of sex partners prior 12 months | 1.5 (1–6) | 8.5 (2–26)** | 6.5 (2–8)* | 0.5174 | 7 (1–12)* |
Baseline immunological profile
HIV-infected Controls | HIV-infected | HIV-uninfected | |||
---|---|---|---|---|---|
Primary/Secondary Syphilis#
| Latent Syphilis#
| Primary/Secondary Syphilis#
| PSS HIV+ vs. -, P$
| ||
Baseline | |||||
N | 30 | 44 | 35 | 10 | |
Pro-inflammatory | |||||
IFNα | 9.88 (1.6–16.43) | 7.45 (0.8–31.35) | 7.45 (0.8–20.42) | 4.12 (0.8–24.73) | 0.5202 |
IL1β | 1.57 (1.57–1.57) | 1.57 (1.57–1.57) | 1.57 (1.57–1.57) | 1.57 (1.57–1.57) | 0.4883 |
IL-6 | 1.26 (1.26–1.26) | 1.26 (1.26–1.26)* | 1.26 (1.26–1.26) | 1.26 (1.26–1.26) | 0.722 |
IL-17A | 1.52 (1.52–1.52) | 1.52 (1.52–1.52) | 1.52 (1.52–1.52) | 1.52 (1.52–1.52) | 0.8358 |
Th1 | |||||
IFNγ | 2.18 (1.54–4.59) | 3.52 (1.54–5.45) | 1.79 (1.54–4.59) | 4.01 (1.54–16.66) | 0.5991 |
IL-7 | 1.11 (1.11–1.11) | 1.11 (1.11–1.36) | 1.11 (1.11–1.11) | 1.11 (1.11–1.11) | 0.357 |
IL-12p40 | 1.02 (1.02–1.02) | 1.02 (1.02–1.02) | 1.02 (1.02–1.02) | 1.02 (1.02–1.02) | 0.4056 |
IL-12p70 | 1.61 (1.61–1.61) | 1.61 (1.61–1.67) | 1.61 (1.61–1.61) | 1.61 (1.61–4.08) | 0.6264 |
Chemokines | |||||
IL-8 | 1.6 (1.6–5.06) | 4.51 (2.41–7.43)** | 1.6 (1.6–3.15) | 1.6 (1.6–5.13) | 0.0723 |
IP-10 | 589.4 (319.38–917.05) | 1016.1 (649.64–1451.32)** | 696.89 (455.35–1101.67) | 696.52 (426.27–1040.07) | 0.1561 |
MCP-1 | 258.42 (179.09–307.75) | 260.1 (216.95–307.35) | 242.05 (180.35–303.1) | 247.64 (205.76–287.32) | 0.4321 |
MIP-1α | 1.63 (1.63–3.65) | 3.09 (1.63–8.3) | 1.63 (1.63–1.63) | 1.63 (1.63–1.63) | 0.1247 |
MIP-1β | 14.54 (0.99–22.23) | 28.59 (16.06–42.51)** | 15.2 (4.92–22.23) | 8.46 (4.92–23.05) | 0.0205 |
Th2 | |||||
IL-4 | 1.58 (1.58–1.58) | 1.58 (1.58–1.58) | 1.58 (1.58–1.58) | 1.58 (1.58–1.58) | 0.4883 |
IL-5 | 1.58 (1.58–1.58) | 1.58 (1.58–1.58) | 1.58 (1.58–1.58) | 1.58 (1.58–1.58) | 0.3324 |
Anti-inflammatory | |||||
IL-10 | 1.55 (1.55–1.55) | 25.3 (4.56–41.76)*** | 2.46 (1.55–4.62)* | 2.73 (1.55–9.02)* | 0.0029 |
6 month | |||||
N | 41 | 34 | 10 | ||
Pro-inflammatory | |||||
IFNα | 0.8 (0.8–9.27)**#
| 0.8 (0.8–7.8)**#
| 0.8 (0.8–0.8)*#
| 0.3282 | |
IL-1β | 1.57 (1.57–1.57) | 1.57 (1.57–1.57) | 1.57 (1.57–1.57) | 0.1798 | |
IL-6 | 1.26 (1.26–1.26) | 1.26 (1.26–1.26) | 1.26 (1.26–1.26) | 0.7379 | |
IL-17A | 1.52 (1.52–1.52) | 1.52 (1.52–1.52) | 1.52 (1.52–1.52) | 0.7379 | |
Th1 | |||||
IFNγ | 1.54 (1.54–5.09) | 1.62 (1.54–4.88) | 5.17 (1.54–13.89) | 0.0978 | |
IL-7 | 1.11 (1.11–1.11) | 1.11 (1.11–1.11) | 1.11 (1.11–1.11) | 0.6486 | |
IL-12p40 | 1.02 (1.02–1.02) | 1.02 (1.02–1.02) | 1.02 (1.02–1.02) | 0.2068 | |
IL-12p70 | 1.61 (1.61–1.61) | 1.61 (1.61–1.86) | 1.61 (1.61–1.61) | 0.7639 | |
Chemokines | |||||
IL-8 | 1.87 (1.6–4.02) | 1.6 (1.6–1.7) | 1.66 (1.6–3.75) | 0.4406 | |
IP-10 | 564.56 (392.18–740.03) | 592.04 (447.8–831.96) | 447 (309–593) | 0.2134 | |
MCP-1 | 270.25 (225.5–330.3) | 261.32 (241.06–312.26) | 269 (219–297) | 0.8287 | |
MIP-1α | 1.63 (1.63–1.63) | 1.63 (1.63–1.63) | 1.63 (1.63–1.63) | 0.6726 | |
MIP-1β | 7.4 (0.99–20.28) | 9.17 (1.99–14) | 2.39 (0.99–12.05) | 0.249 | |
Th2 | |||||
IL-4 | 1.58 (1.58–1.58) | 1.58 (1.58–1.58) | 1.58 (1.58–1.58) | 0.1798 | |
IL-5 | 1.58 (1.58–1.58) | 1.58 (1.58–1.58) | 1.58 (1.58–1.58) | 0.3621 | |
Anti-inflammatory | |||||
IL-10 | 1.83 (1.83–4.09)*** | 2.11 (1.83–3.37)*** | 2.26 (1.83–4.46)** | 0.6296 |